Loading...
XNAS
ALXO
Market cap30mUSD
Jun 09, Last price  
0.58USD
1D
-0.05%
1Q
-40.55%
IPO
-98.09%
Name

ALX Oncology Holdings Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
7.42%
Rev. gr., 5y
-13.11%
Revenues
0k
2,067,0004,796,0001,182,0000000
Net income
-135m
L-16.14%
-13,731,000-19,243,000-45,740,000-83,463,000-123,482,000-160,805,000-134,850,000
CFO
-122m
L-6.48%
-13,190,000-14,249,000-38,289,000-68,101,000-89,223,000-130,364,000-121,912,000
Earnings
Aug 06, 2025

Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
IPO date
Jul 17, 2020
Employees
72
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
142,467
171,114
128,902
Unusual Expense (Income)
NOPBT
(142,467)
(171,114)
(128,902)
NOPBT Margin
Operating Taxes
64
Tax Rate
NOPAT
(142,467)
(171,114)
(128,966)
Net income
(134,850)
-16.14%
(160,805)
30.23%
(123,482)
47.95%
Dividends
Dividend yield
Proceeds from repurchase of equity
351
58,887
1,239
BB yield
-0.40%
-9.20%
-0.27%
Debt
Debt current
435
1,575
1,041
Long-term debt
23,180
10,430
Deferred revenue
Other long-term liabilities
15,657
1,218
5,311
Net debt
(130,846)
(193,392)
(288,134)
Cash flow
Cash from operating activities
(121,912)
(130,364)
(89,223)
CAPEX
(447)
(1,274)
(1,427)
Cash from investing activities
86,256
44,657
(235,416)
Cash from financing activities
30,817
59,291
9,860
FCF
(134,531)
(172,142)
(135,307)
Balance
Cash
127,757
182,736
282,906
Long term investments
3,524
35,411
16,699
Excess cash
131,281
218,147
299,605
Stockholders' equity
(620,794)
(485,966)
(326,271)
Invested Capital
750,504
694,093
16,545
ROIC
ROCE
EV
Common stock shares outstanding
52,175
42,988
40,700
Price
1.67
-88.78%
14.89
32.12%
11.27
-47.56%
Market cap
87,132
-86.39%
640,088
39.55%
458,685
-47.05%
EV
(43,714)
446,696
170,551
EBITDA
(141,595)
(170,278)
(128,560)
EV/EBITDA
0.31
Interest
1,729
1,565
4,360
Interest/NOPBT